CoreCap Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

CoreCap Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.5K	Hold	370	–	–	﹤0.01%	1884
2026 Q2	$29.3K	Hold	370	–	–	﹤0.01%	1643
2026 Q1	$27.8K	Hold	370	–	–	﹤0.01%	1540
2025 Q4	$29.3K	Buy	370 +325	+722%	+$24.5K	﹤0.01%	1531
2025 Q3	$2.94K	Hold	45	–	–	﹤0.01%	2300
2025 Q2	$1.78K	Sell	45 -7	-13%	-$229	﹤0.01%	2328
2025 Q1	$1.57K	Buy	52 +7	+16%	+$229	﹤0.01%	2428
2024 Q4	$1.57K	Buy	45 +19	+73%	+$710	﹤0.01%	2286
2024 Q3	$1.04K	Buy	+26	New	+$1.21K	﹤0.01%	2266
2024 Q2	–	Sell	-26	Closed	-$1.13K	–	2086
2024 Q1	$1.13K	Buy	+26	New	+$1.24K	﹤0.01%	2208
2022 Q4	$982	Buy	+26	New	+$1.09K	﹤0.01%	2057
2022 Q3	–	Sell	-64	Closed	-$2K	–	1276
2022 Q2	$2K	Buy	+64	New	+$2.41K	﹤0.01%	1872
2022 Q1	–	Sell	-102	Closed	-$3K	–	1277
2021 Q4	$3K	Buy	+102	New	+$3.21K	﹤0.01%	1875

Other funds holding IONS

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

CoreCap Advisors's IONS Position: Q3 2026 in Review

CoreCap Advisors held its Ionis Pharmaceuticals (IONS) position steady in Q3 2026 at 370 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1884.

CoreCap Advisors first reported a position in IONS in Q4 2021 and has held it in 13 quarters since. The position peaked at $29.3K in Q2 2026. 60 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

CoreCap Advisors held 370 shares of Ionis Pharmaceuticals worth $16.5K as of Q3 2026.
CoreCap Advisors left its Ionis Pharmaceuticals share count unchanged in Q3 2026.
Ionis Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1884 holding.
CoreCap Advisors first reported a position in Ionis Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
CoreCap Advisors's Ionis Pharmaceuticals position peaked at $29.3K in Q2 2026.
60 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.